Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 72
Filter
1.
Sci Rep ; 10(1): 14877, 2020 09 10.
Article in English | MEDLINE | ID: mdl-32913236

ABSTRACT

Fatty-acid(FA)-synthase(FASN) is a druggable lipogenic oncoprotein whose blockade causes metabolic disruption. Whether drug-induced metabolic perturbation is essential for anticancer drug-action, or is just a secondary-maybe even a defence response-is still unclear. To address this, SKOV3 and OVCAR3 ovarian cancer(OC) cell lines with clear cell and serous histology, two main OC subtypes, were exposed to FASN-inhibitor G28UCM. Growth-inhibition was compared with treatment-induced cell-metabolomes, lipidomes, proteomes and kinomes. SKOV3 and OVCAR3 were equally sensitive to low-dose G28UCM, but SKOV3 was more resistant than OVCAR3 to higher concentrations. Metabolite levels generally decreased upon treatment, but individual acylcarnitines, glycerophospholipids, sphingolipids, amino-acids, biogenic amines, and monosaccharides reacted differently. Drug-induced effects on central-carbon-metabolism and oxidative-phosphorylation (OXPHOS) were essentially different in the two cell lines, since drug-naïve SKOV3 are known to prefer glycolysis, while OVCAR3 favour OXPHOS. Moreover, drug-dependent increase of desaturases and polyunsaturated-fatty-acids (PUFAs) were more pronounced in SKOV3 and appear to correlate with G28UCM-tolerance. In contrast, expression and phosphorylation of proteins that control apoptosis, FA synthesis and membrane-related processes (beta-oxidation, membrane-maintenance, transport, translation, signalling and stress-response) were concordantly affected. Overall, membrane-disruption and second-messenger-silencing were crucial for anticancer drug-action, while metabolic-rewiring was only secondary and may support high-dose-FASN-inhibitor-tolerance. These findings may guide future anti-metabolic cancer intervention.


Subject(s)
Cell Membrane/drug effects , Fatty Acid Synthase, Type I/antagonists & inhibitors , Gallic Acid/analogs & derivatives , Lipidomics/methods , Naphthalenes/pharmacology , Ovarian Neoplasms/drug therapy , Proteome/metabolism , Cell Line, Tumor , Cell Membrane/chemistry , Cell Membrane/metabolism , Cell Proliferation , Drug Resistance, Neoplasm , Fatty Acid Synthase, Type I/metabolism , Fatty Acid Synthesis Inhibitors/pharmacology , Female , Gallic Acid/pharmacology , Humans , Metabolome , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Signal Transduction
3.
FEBS J ; 287(21): 4710-4728, 2020 11.
Article in English | MEDLINE | ID: mdl-32112503

ABSTRACT

The synthetic biocide triclosan targets enoyl-acyl carrier protein reductase(s) (ENR) in bacterial type II fatty acid biosynthesis. Screening and sequence analyses of the triclosan resistome from the soil metagenome identified a variety of triclosan-resistance ENRs. Interestingly, the mode of triclosan resistance by one hypothetical protein was elusive, mainly due to a lack of sequence similarity with other proteins that mediate triclosan resistance. Here, we carried out a structure-based function prediction of the hypothetical protein, herein referred to as FabMG, and in vivo and in vitro functional analyses. The crystal structure of FabMG showed limited structural homology with FabG and FabI, which are also involved in type II fatty acid synthesis. In vivo complementation and in vitro activity assays indicated that FabMG is functionally a FabI-type ENR that employs NADH as a coenzyme. Variations in the sequence and structure of FabMG are likely responsible for inefficient binding of triclosan, resulting in triclosan resistance. These data unravel a previously uncharacterized FabMG, which is prevalent in various microbes in triclosan-contaminated environments and provide mechanistic insight into triclosan resistance.


Subject(s)
Bacteria/genetics , Bacterial Proteins/genetics , Drug Resistance, Bacterial/genetics , Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)/genetics , Metagenome/genetics , Triclosan/pharmacology , Amino Acid Sequence , Bacteria/metabolism , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Biocatalysis/drug effects , Crystallography, X-Ray , Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)/classification , Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)/metabolism , Fatty Acid Synthesis Inhibitors/pharmacology , Models, Molecular , Phylogeny , Protein Conformation , Sequence Homology, Amino Acid , Soil Microbiology
4.
J Biochem Mol Toxicol ; 34(1): e22413, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31714634

ABSTRACT

Hepatic diseases leading to fibrosis affect millions of individuals worldwide and are a major public health challenge. Although, there have been many advances in understanding hepatic fibrogenesis, an effective therapy remains elusive. Studies focus primarily on activation of the hepatic stellate cells (HSCs), the principal fibrogenic cells in the liver; however, fewer numbers of studies have examined molecular mechanisms that deactivate HSC, controlling the profibrogenic phenotype. In the present study, we evaluated cellular and molecular actions of the chemical triclosan (TCS) in reverting activated HSCs to a quiesced phenotype. We demonstrated that the inhibition of the enzyme fatty acid synthase by TCS in activated HSCs promotes survival of the cells and triggers cellular and molecular changes that promote cellular phenotypic reversion, offering potentially new therapeutic directions.


Subject(s)
Fatty Acid Synthesis Inhibitors/pharmacology , Hepatic Stellate Cells/drug effects , Triclosan/pharmacology , Cell Line , Cell Survival/drug effects , Fatty Acid Synthases/antagonists & inhibitors , Hepatic Stellate Cells/cytology , Humans
5.
Am J Physiol Endocrinol Metab ; 318(2): E262-E275, 2020 02 01.
Article in English | MEDLINE | ID: mdl-31821038

ABSTRACT

miR-130b is a microRNA whose expression is particularly elevated within adipose tissue and in the circulation in diabetic states. Hepatic miR-130b expression has been linked to hepatocellular carcinoma and changes in lipid metabolism. Here, we investigated the role of miR-130b in hepatic lipid homeostasis and lipoprotein export. We observed that overexpression of miR-130b-3p or -5p in HepG2 cells markedly enhanced the secretion of very-low-density lipoprotein (VLDL) particles, enhanced the secretion of [3H]glycerol metabolically labeled triglyceride (TG), and significantly increased the number or the average size of lipid droplets (LDs), respectively. Overexpression of miR-130b also altered the expression of key genes involved in lipid metabolism and in particular markedly increased both mRNA and protein expression levels of microsomal triglyceride transfer protein (MTP). Conversely, the miR-130b inhibitor decreased mRNA levels of MTP and fatty acid synthase (FAS) in HepG2 cells. However, dual-luciferase reporter assays indicated that MTP is not a direct target of miR-130b-3p. miR-130b overexpression did not alter de novo synthesized TG or the stability and secretion of apolipoprotein B 100. Interestingly, knockdown of phosphatase and tensin homolog (PTEN) blocked the upregulation of MTP mRNA induced by miR-130b. Finally, miR-130b-induced stimulation of VLDL secretion was also observed in a second hepatocyte cell culture model, immortalized human hepatocytes, confirming the effects observed in HepG2 cells. Overall, these data suggest a potential role for miR-130b in promoting hepatic VLDL assembly and secretion mediated by marked stimulation of MTP expression and TG mobilization. Thus miR-130b overexpression corrects the defect in VLDL production in HepG2 cells.


Subject(s)
Carrier Proteins/biosynthesis , Lipoproteins, VLDL/biosynthesis , Lipoproteins, VLDL/metabolism , Liver/metabolism , MicroRNAs/metabolism , Microsomes, Liver/enzymology , Apolipoprotein B-100/biosynthesis , Apolipoprotein B-100/genetics , Cell Line , Cells, Cultured , Fatty Acid Synthesis Inhibitors/pharmacology , Gene Knockdown Techniques , Hepatocytes/metabolism , Humans , Lipid Metabolism/genetics , MicroRNAs/antagonists & inhibitors , MicroRNAs/genetics , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/metabolism
6.
Sci Rep ; 9(1): 13284, 2019 09 16.
Article in English | MEDLINE | ID: mdl-31527721

ABSTRACT

Elevated fatty acid synthase (FASN) has been reported in both androgen-dependent and -independent prostate cancers. Conventional treatment for prostate cancer is radiotherapy (RT); however, the following radiation-induced radioresistance often causes treatment failure. Upstream proteins of FASN such as Akt and NF-κB are found increased in the radioresistant prostate cancer cells. Nevertheless, whether inhibition of FASN could improve RT outcomes and reverse radiosensitivity of prostate cancer cells is still unknown. Here, we hypothesised that orlistat, a FASN inhibitor, could improve RT outcomes in prostate cancer. Orlistat treatment significantly reduced the S phase population in both androgen-dependent and -independent prostate cancer cells. Combination of orlistat and RT significantly decreased NF-κB activity and related downstream proteins in both prostate cancer cells. Combination effect of orlistat and RT was further investigated in both LNCaP and PC3 tumour-bearing mice. Combination treatment showed the best tumour inhibition compared to that of orlistat alone or RT alone. These results suggest that prostate cancer treated by conventional RT could be improved by orlistat via inhibition of FASN.


Subject(s)
Fatty Acid Synthase, Type I/antagonists & inhibitors , Fatty Acid Synthesis Inhibitors/pharmacology , Orlistat/pharmacology , Prostatic Neoplasms/radiotherapy , Radiation-Sensitizing Agents/pharmacology , Animals , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Fatty Acid Synthase, Type I/metabolism , Humans , Male , Mice , Mice, Nude , NF-kappa B/metabolism , PC-3 Cells , Prostate/pathology , Prostatic Neoplasms/pathology
7.
Appl Microbiol Biotechnol ; 102(24): 10603-10612, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30276713

ABSTRACT

We have recently developed Corynebacterium glutamicum strains that produce free fatty acids in culture supernatant due to enhanced fatty acid biosynthesis. Of these producing strains, the basic producer PAS-15 has a defect in the gene for a fatty acid biosynthesis repressor protein, and the advanced producer PCC-6 has two additional mutations to augment the production by strain PAS-15. The aim of the present study was to obtain novel genetic traits for improving fatty acid production by these producers. A new mutant with increased production derived from strain PAS-15 had a missense mutation in the accD3 gene (mutation accD3A433T), which is involved in the biosynthesis of mycolic acids that are cell envelope lipids of C. glutamicum, as the causal mutation. Mutation accD3A433T was verified to reduce the AccD3 enzymatic activity and increase fatty acid production in strain PAS-15 by 1.8-fold. Deletion of the accD3 gene in strain PAS-15, which was motivated by the characteristic of mutation accD3A433T, increased fatty acid production by 3.2-fold. Susceptibility of strain PAS-15 to vancomycin was significantly increased by accD3 gene deletion and by mutation accD3A433T to the intermediate level, suggesting that the cell envelope permeability barrier by mycolic acids is weakened by this engineering. Furthermore, mutation accD3A433T also increased fatty acid production in strain PCC-6 by 1.3-fold. These increased production levels were suggested to be involved not only in the redirection of carbon flux from mycolic acid biosynthesis to fatty acid production but also in the permeability of the cell envelope.


Subject(s)
Corynebacterium glutamicum/genetics , Corynebacterium glutamicum/metabolism , Mycolic Acids/metabolism , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cerulenin/pharmacology , Corynebacterium glutamicum/drug effects , Fatty Acid Synthesis Inhibitors/pharmacology , Fatty Acids/metabolism , Microorganisms, Genetically-Modified , Mutation , Vancomycin/pharmacology
8.
Plant Physiol ; 178(3): 1112-1129, 2018 11.
Article in English | MEDLINE | ID: mdl-30181343

ABSTRACT

Fatty acids are synthesized in the stroma of plant and algal chloroplasts by the fatty acid synthase complex. Newly synthesized fatty acids are then used to generate plastidial lipids that are essential for chloroplast structure and function. Here, we show that inhibition of fatty acid synthesis in the model alga Chlamydomonas reinhardtii activates autophagy, a highly conserved catabolic process by which cells degrade intracellular material under adverse conditions to maintain cell homeostasis. Treatment of Chlamydomonas cells with cerulenin, a specific fatty acid synthase inhibitor, stimulated lipidation of the autophagosome protein ATG8 and enhanced autophagic flux. We found that inhibition of fatty acid synthesis decreased monogalactosyldiacylglycerol abundance, increased lutein content, down-regulated photosynthesis, and increased the production of reactive oxygen species. Electron microscopy revealed a high degree of thylakoid membrane stacking in cerulenin-treated cells. Moreover, global transcriptomic analysis of these cells showed an up-regulation of genes encoding chloroplast proteins involved in protein folding and oxidative stress and the induction of major catabolic processes, including autophagy and proteasome pathways. Thus, our results uncovered a link between lipid metabolism, chloroplast integrity, and autophagy through a mechanism that involves the activation of a chloroplast quality control system.


Subject(s)
Autophagy/drug effects , Chlamydomonas reinhardtii/physiology , Fatty Acid Synthases/antagonists & inhibitors , Fatty Acids/metabolism , Lipid Metabolism/drug effects , Cerulenin/pharmacology , Chlamydomonas reinhardtii/drug effects , Chlamydomonas reinhardtii/genetics , Chlamydomonas reinhardtii/ultrastructure , Chloroplasts/drug effects , Chloroplasts/physiology , Chloroplasts/ultrastructure , Endoplasmic Reticulum/metabolism , Fatty Acid Synthesis Inhibitors/pharmacology , Gene Expression Regulation, Plant/drug effects , Oxidative Stress , Photosynthesis , Plant Proteins/antagonists & inhibitors , Protein Folding , Reactive Oxygen Species/metabolism , Up-Regulation
9.
Pestic Biochem Physiol ; 148: 116-125, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29891362

ABSTRACT

The prevalent occurrence of herbicide resistant weeds increases the necessity for new site of action herbicides for effective control as well as to relax selection pressure on the known sites of action. As a consequence, interest increased in the unexploited molecule cinmethylin as a new solution for the control of weedy grasses in cereals. Therefore, the mechanism of action of cinmethylin was reevaluated. We applied the chemoproteomic approach cellular Target Profiling™ from Evotec to identify the cinmethylin target in Lemna paucicostata protein extracts. We found three potential targets belonging to the same protein family of fatty acid thioesterases (FAT) to bind to cinmethylin with high affinity. Binding of cinmethylin to FAT proteins from Lemna and Arabidopsis was confirmed by fluorescence-based thermal shift assay. The plastid localized enzyme FAT plays a crucial role in plant lipid biosynthesis, by mediating the release of fatty acids (FA) from its acyl carrier protein (ACP) which is necessary for FA export to the endoplasmic reticulum. GC-MS analysis of free FA composition in Lemna extracts revealed strong reduction of unsaturated C18 as well as saturated C14, and C16 FAs upon treatment with cinmethylin, indicating that FA release for subsequent lipid biosynthesis is the primary target of cinmethylin. Lipid biosynthesis is a prominent target of different herbicide classes. To assess whether FAT inhibition constitutes a new mechanism of action within this complex pathway, we compared physiological effects of cinmethylin to different ACCase and VLCFA synthesis inhibitors and identified characteristic differences in plant symptomology and free FA composition upon treatment with the three herbicide classes. Also, principal component analysis of total metabolic profiling of treated Lemna plants showed strong differences in overall metabolic changes after cinmethylin, ACCase or VLCFA inhibitor treatments. Our results identified and confirmed FAT as the cinmethylin target and validate FAT inhibition as a new site of action different from other lipid biosynthesis inhibitor classes.


Subject(s)
Arabidopsis/drug effects , Araceae/drug effects , Fatty Acids/antagonists & inhibitors , Herbicides/metabolism , Plant Proteins/metabolism , Thiolester Hydrolases/metabolism , Arabidopsis/metabolism , Araceae/metabolism , Biological Transport , Crystallography, X-Ray , Endoplasmic Reticulum/metabolism , Fatty Acid Synthesis Inhibitors/metabolism , Fatty Acid Synthesis Inhibitors/pharmacology , Fatty Acids/biosynthesis , Fluorescence , Gas Chromatography-Mass Spectrometry , Herbicide Resistance , Herbicides/pharmacology , Principal Component Analysis , Protein Conformation , Thiolester Hydrolases/chemistry
10.
Article in English | MEDLINE | ID: mdl-29661867

ABSTRACT

One of the most important clinical obstacles in cystic fibrosis (CF) treatment is antibiotic treatment failure due to biofilms produced by Pseudomonas aeruginosa The ability of this pathogen to survive eradication by tobramycin and pathoadapt into a hyperbiofilm state leading to chronic infections is key to its success. Retrospective studies have demonstrated that preventing this pathoadaptation by improving eradication is essential to extend the lives of CF patients. To identify adjuvants that enhance tobramycin eradication of P. aeruginosa, we performed a high-throughput screen of 6,080 compounds from four drug-repurposing libraries. We identified that the Food and Drug Administration (FDA)-approved compound triclosan, in combination with tobramycin, resulted in a 100-fold reduction of viable cells within biofilms at 6 h, but neither compound alone had significant antimicrobial activity against biofilms. This synergistic treatment significantly accelerated the killing of biofilms compared to that with tobramycin treatment alone, and the combination was effective against 6/7 CF clinical isolates compared to tobramycin treatment alone, including a tobramycin-resistant strain. Further, triclosan and tobramycin killed persister cells, causing a 100-fold reduction by 8 h and complete eradication by 24 h. Triclosan also enhances tobramycin killing of multiple Burkholderia cenocepacia and Staphylococcus aureus clinical isolates grown as biofilms. Additionally, triclosan showed synergy with other aminoglycosides, such as gentamicin or streptomycin. Triclosan is a well-tolerated aminoglycoside adjuvant shown to be safe for human use that could improve the treatment of biofilm-based infections.


Subject(s)
Adjuvants, Pharmaceutic/pharmacology , Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Fatty Acid Synthesis Inhibitors/pharmacology , Pseudomonas aeruginosa/drug effects , Tobramycin/pharmacology , Triclosan/pharmacology , Biofilms/growth & development , Cystic Fibrosis/drug therapy , Drug Synergism , Drug Therapy, Combination , High-Throughput Screening Assays , Humans , Microbial Sensitivity Tests , Pseudomonas aeruginosa/isolation & purification
11.
Vet J ; 230: 62-64, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29102599

ABSTRACT

The recent outbreak of infection with Zika virus (ZIKV; Flaviviridae) has attracted attention to this previously neglected mosquito-borne pathogen and the need for efficient therapies. Since flavivirus replication is generally known to be dependent on fatty acid biosynthesis, two inhibitors of this pathway, 5-(tetradecyloxyl)-2-furoic acid (TOFA) and cerulenin, were tested for their potentiality to inhibit virus replication. At concentrations previously shown to inhibit the replication of other flaviviruses, neither drug had a significant antiviral affect against ZIKV, but reduced the replication of the non-related mosquito-borne Semliki Forest virus (Togaviridae).


Subject(s)
Antiviral Agents/pharmacology , Cerulenin/pharmacology , Fatty Acid Synthesis Inhibitors/pharmacology , Furans/pharmacology , Hypolipidemic Agents/pharmacology , Semliki forest virus/drug effects , Zika Virus/drug effects , A549 Cells/virology , Dose-Response Relationship, Drug , Humans , Virus Replication/drug effects
12.
Article in English | MEDLINE | ID: mdl-28784680

ABSTRACT

The type II fatty acid synthesis (FASII) pathway is essential for bacterial lipid biosynthesis and continues to be a promising target for novel antibacterial compounds. Recently, it has been demonstrated that Chlamydia is capable of FASII and this pathway is indispensable for Chlamydia growth. Previously, a high-content screen with Chlamydia trachomatis-infected cells was performed, and acylated sulfonamides were identified to be potent growth inhibitors of the bacteria. C. trachomatis strains resistant to acylated sulfonamides were isolated by serial passage of a wild-type strain in the presence of low compound concentrations. Results from whole-genome sequencing of 10 isolates from two independent drug-resistant populations revealed that mutations that accumulated in fabF were predominant. Studies of the interaction between the FabF protein and small molecules showed that acylated sulfonamides directly bind to recombinant FabF in vitro and treatment of C. trachomatis-infected HeLa cells with the compounds leads to a decrease in the synthesis of Chlamydia fatty acids. This work demonstrates the importance of FASII for Chlamydia development and may lead to the development of new antimicrobials.


Subject(s)
Anti-Bacterial Agents/pharmacology , Chlamydia trachomatis/drug effects , Fatty Acid Synthase, Type II/metabolism , Fatty Acid Synthesis Inhibitors/pharmacology , Fatty Acids/biosynthesis , Sulfamethoxazole/pharmacology , Acylation/drug effects , Adamantane/pharmacology , Aminobenzoates/pharmacology , Anilides/pharmacology , Animals , Cell Line, Tumor , Cerulenin/pharmacology , Chlamydia Infections/drug therapy , Chlamydia Infections/microbiology , Chlamydia trachomatis/genetics , Chlamydia trachomatis/metabolism , Chlorocebus aethiops , Fatty Acid Synthase, Type II/genetics , HeLa Cells , Humans , Triclosan/pharmacology , Vero Cells
13.
Int J Mol Sci ; 18(6)2017 May 31.
Article in English | MEDLINE | ID: mdl-28561793

ABSTRACT

This study determined the comparative nephrotoxic potential of four trichloronitrobenzenes (TCNBs) (2,3,4-; 2,4,5-; 2,4,6-; and 3,4,5-TCNB) and explored the effects of antioxidants and biotransformation inhibitors on TCNB-induced cytotoxicity in isolated renal cortical cells (IRCC) from male Fischer 344 rats. IRCC were incubated with a TCNB up to 1.0 mM for 15-120 min. Pretreatment with an antioxidant or cytochrome P450 (CYP), flavin monooxygenase (FMO), or peroxidase inhibitor was used in some experiments. Among the four TCNBs, the order of decreasing nephrotoxic potential was approximately 3,4,5- > 2,4,6- > 2,3,4- > 2,4,5-TCNB. The four TCNBs exhibited a similar profile of attenuation of cytotoxicity in response to antioxidant pretreatments. 2,3,4- and 3,4,5-TCNB cytotoxicity was attenuated by most of the biotransformation inhibitors tested, 2,4,5-TCNB cytotoxicity was only inhibited by isoniazid (CYP 2E1 inhibitor), and 2,4,6-TCNB-induced cytotoxicity was inhibited by one CYP inhibitor, one FMO inhibitor, and one peroxidase inhibitor. All of the CYP specific inhibitors tested offered some attenuation of 3,4,5-TCNB cytotoxicity. These results indicate that 3,4,5-TCNB is the most potent nephrotoxicant, free radicals play a role in the TCNB cytotoxicity, and the role of biotransformation in TCNB nephrotoxicity in vitro is variable and dependent on the position of the chloro groups.


Subject(s)
Free Radicals/metabolism , Kidney Cortex/drug effects , Animals , Antioxidants/pharmacology , Biotransformation/drug effects , Cell Survival/drug effects , Cytochrome P-450 Enzyme Inhibitors/pharmacology , Fatty Acid Synthesis Inhibitors/pharmacology , Hydrocarbons, Chlorinated , Isoniazid/pharmacology , Kidney Cortex/cytology , Kidney Cortex/metabolism , Male , Rats, Inbred F344
14.
PLoS Biol ; 15(5): e2002214, 2017 05.
Article in English | MEDLINE | ID: mdl-28542493

ABSTRACT

Examining the fundamental structure and processes of living cells at the nanoscale poses a unique analytical challenge, as cells are dynamic, chemically diverse, and fragile. A case in point is the cell membrane, which is too small to be seen directly with optical microscopy and provides little observational contrast for other methods. As a consequence, nanoscale characterization of the membrane has been performed ex vivo or in the presence of exogenous labels used to enhance contrast and impart specificity. Here, we introduce an isotopic labeling strategy in the gram-positive bacterium Bacillus subtilis to investigate the nanoscale structure and organization of its plasma membrane in vivo. Through genetic and chemical manipulation of the organism, we labeled the cell and its membrane independently with specific amounts of hydrogen (H) and deuterium (D). These isotopes have different neutron scattering properties without altering the chemical composition of the cells. From neutron scattering spectra, we confirmed that the B. subtilis cell membrane is lamellar and determined that its average hydrophobic thickness is 24.3 ± 0.9 Ångstroms (Å). Furthermore, by creating neutron contrast within the plane of the membrane using a mixture of H- and D-fatty acids, we detected lateral features smaller than 40 nm that are consistent with the notion of lipid rafts. These experiments-performed under biologically relevant conditions-answer long-standing questions in membrane biology and illustrate a fundamentally new approach for systematic in vivo investigations of cell membrane structure.


Subject(s)
Bacillus subtilis/metabolism , Cell Membrane/metabolism , Fatty Acids/metabolism , Lipid Bilayers/metabolism , Membrane Microdomains/metabolism , Models, Biological , Algorithms , Bacillus subtilis/chemistry , Bacillus subtilis/drug effects , Bacillus subtilis/growth & development , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cell Membrane/chemistry , Cell Membrane/drug effects , Cerulenin/pharmacology , Deuterium , Enoyl-CoA Hydratase/genetics , Enoyl-CoA Hydratase/metabolism , Fatty Acid Synthesis Inhibitors/pharmacology , Fatty Acids/chemistry , Gene Deletion , Hydrophobic and Hydrophilic Interactions , Lipid Bilayers/chemistry , Membrane Microdomains/chemistry , Membrane Microdomains/drug effects , Microbial Viability/drug effects , Neutron Diffraction , Palmitic Acids/chemistry , Palmitic Acids/metabolism , Scattering, Small Angle , Stereoisomerism
15.
Article in English | MEDLINE | ID: mdl-28193654

ABSTRACT

The need for new antimicrobials to treat bacterial infections has led to the use of type II fatty acid synthesis (FASII) enzymes as front-line targets. However, recent studies suggest that FASII inhibitors may not work against the opportunist pathogen Staphylococcus aureus, as environmental fatty acids favor emergence of multi-anti-FASII resistance. As fatty acids are abundant in the host and one FASII inhibitor, triclosan, is widespread, we investigated whether fatty acid pools impact resistance in clinical and veterinary S. aureus isolates. Simple addition of fatty acids to the screening medium led to a 50% increase in triclosan resistance, as tested in 700 isolates. Moreover, nonculturable triclosan-resistant fatty acid auxotrophs, which escape detection under routine conditions, were uncovered in primary patient samples. FASII bypass in selected isolates correlated with polymorphisms in the acc and fabD loci. We conclude that fatty-acid-dependent strategies to escape FASII inhibition are common among S. aureus isolates and correlate with anti-FASII resistance and emergence of nonculturable variants.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Infective Agents, Local/pharmacology , Fatty Acid Synthase, Type II/antagonists & inhibitors , Fatty Acid Synthesis Inhibitors/pharmacology , Staphylococcus aureus/drug effects , Triclosan/pharmacology , Animals , Cattle , Drug Resistance, Bacterial/genetics , Fatty Acid Synthase, Type II/genetics , Fatty Acid Synthase, Type II/metabolism , Fatty Acids/metabolism , Humans , Microbial Sensitivity Tests , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus aureus/isolation & purification , Staphylococcus aureus/metabolism
16.
Lab Invest ; 97(2): 194-206, 2017 02.
Article in English | MEDLINE | ID: mdl-27918556

ABSTRACT

Fatty acid synthase (FASN) is responsible for the endogenous production of fatty acids from acetyl-CoA and malonyl-CoA. Its overexpression is associated with poor prognosis in human cancers including melanomas. Our group has previously shown that the inhibition of FASN with orlistat reduces spontaneous lymphatic metastasis in experimental B16-F10 melanomas, which is a consequence, at least in part, of the reduction of proliferation and induction of apoptosis. Here, we sought to investigate the effects of pharmacological FASN inhibition on lymphatic vessels by using cell culture and mouse models. The effects of FASN inhibitors cerulenin and orlistat on the proliferation, apoptosis, and migration of human lymphatic endothelial cells (HDLEC) were evaluated with in vitro models. The lymphatic outgrowth was evaluated by using a murine ex vivo assay. B16-F10 melanomas and surgical wounds were produced in the ears of C57Bl/6 and Balb-C mice, respectively, and their peripheral lymphatic vessels evaluated by fluorescent microlymphangiography. The secretion of vascular endothelial growth factor C and D (VEGF-C and -D) by melanoma cells was evaluated by ELISA and conditioned media used to study in vitro lymphangiogenesis. Here, we show that cerulenin and orlistat decrease the viability, proliferation, and migration of HDLEC cells. The volume of lymph node metastases from B16-F10 experimental melanomas was reduced by 39% in orlistat-treated animals as well as the expression of VEGF-C in these tissues. In addition, lymphatic vessels from orlistat-treated mice drained more efficiently the injected FITC-dextran. Orlistat and cerulenin reduced VEGF-C secretion and, increase production of VEGF-D by B16-F10 and SK-Mel-25 melanoma cells. Finally, reduced lymphatic cell extensions, were observed following the treatment with conditioned medium from cerulenin- and orlistat-treated B16-F10 cells. Altogether, our results show that FASN inhibitors have anti-metastatic effects by acting on lymphatic endothelium and melanoma cells regardless the increase of lymphatic permeability promoted by orlistat.


Subject(s)
Cerulenin/pharmacology , Fatty Acid Synthases/antagonists & inhibitors , Lactones/pharmacology , Lymphatic Vessels/drug effects , Melanoma, Experimental/prevention & control , Animals , Apoptosis/drug effects , Blotting, Western , Cell Line , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Fatty Acid Synthases/genetics , Fatty Acid Synthases/metabolism , Fatty Acid Synthesis Inhibitors/pharmacology , Humans , Lymphangiogenesis/drug effects , Lymphatic Metastasis , Lymphatic Vessels/metabolism , Melanoma/genetics , Melanoma/metabolism , Melanoma/pathology , Melanoma, Experimental/genetics , Melanoma, Experimental/metabolism , Mice, Inbred BALB C , Mice, Inbred C57BL , Orlistat , RNA Interference , Reverse Transcriptase Polymerase Chain Reaction , Vascular Endothelial Growth Factor C/metabolism , Vascular Endothelial Growth Factor D/metabolism
17.
Mol Microbiol ; 103(4): 698-712, 2017 02.
Article in English | MEDLINE | ID: mdl-27875634

ABSTRACT

The stringent response is a universal adaptive mechanism to protect bacteria from nutritional and environmental stresses. The role of the stringent response during lipid starvation has been studied only in Gram-negative bacteria. Here, we report that the stringent response also plays a crucial role in the adaptation of the model Gram-positive Bacillus subtilis to fatty acid starvation. B. subtilis lacking all three (p)ppGpp-synthetases (RelBs , RelP and RelQ) or bearing a RelBs variant that no longer synthesizes (p)ppGpp suffer extreme loss of viability on lipid starvation. Loss of viability is paralleled by perturbation of membrane integrity and function, with collapse of membrane potential as the likely cause of death. Although no increment of (p)ppGpp could be detected in lipid starved B. subtilis, we observed a substantial increase in the GTP/ATP ratio of strains incapable of synthesizing (p)ppGpp. Artificially lowering GTP with decoyinine rescued viability of such strains, confirming observations that low intracellular GTP is important for survival of nutritional stresses. Altogether, our results show that activation of the stringent response by lipid starvation is a broadly conserved response of bacteria and that a key role of (p)ppGpp is to couple biosynthetic processes that become detrimental if uncoordinated.


Subject(s)
Adenosine Triphosphate/metabolism , Bacillus subtilis/growth & development , Bacillus subtilis/metabolism , Fatty Acids/metabolism , Guanosine Triphosphate/metabolism , Ligases/genetics , Membrane Potentials/physiology , Starvation/metabolism , Cerulenin/pharmacology , Fatty Acid Synthesis Inhibitors/pharmacology , Fatty Acids/biosynthesis , Stress, Physiological
18.
PLoS One ; 11(9): e0162861, 2016.
Article in English | MEDLINE | ID: mdl-27649078

ABSTRACT

The gene encoding phosphopantetheinyl transferase (PPTase), pfaE, a component of the polyketide synthase (PKS) pathway, is crucial for the production of docosahexaenoic acid (DHA, 22:6ω3), along with the other pfa cluster members pfaA, pfaB, pfaC and pfaD. DHA was produced in Escherichia coli by co-expressing pfaABCD from DHA-producing Colwellia psychrerythraea 34H with one of four pfaE genes from bacteria producing arachidonic acid (ARA, 20:4ω6), eicosapentaenoic acid (EPA, 20:5ω3) or DHA, respectively. Substitution of the pfaE gene from different strain source in E. coli did not influence the function of the PKS pathway producing DHA, although they led to different DHA yields and fatty acid profiles. This result suggested that the pfaE gene could be switchable between these strains for the production of DHA. The DHA production by expressing the reconstituted PKS pathway was also investigated in different E. coli strains, at different temperatures, or with the treatment of cerulenin. The highest DHA production, 2.2 mg of DHA per gram of dry cell weight or 4.1% of total fatty acids, was obtained by co-expressing pfaE(EPA) from the EPA-producing strain Shewanella baltica with pfaABCD in DH5α. Incubation at low temperature (10-15°C) resulted in higher accumulation of DHA compared to higher temperatures. The addition of cerulenin to the medium increased the proportion of DHA and saturated fatty acids, including C12:0, C14:0 and C16:0, at the expense of monounsaturated fatty acids, including C16:1 and C18:1. Supplementation with 1 mg/L cerulenin resulted in the highest DHA yield of 2.4 mg/L upon co-expression of pfaE(DHA) from C. psychrerythraea.


Subject(s)
Alteromonadaceae/enzymology , Bacterial Proteins/metabolism , Docosahexaenoic Acids/biosynthesis , Escherichia coli/metabolism , Polyketide Synthases/metabolism , Transferases (Other Substituted Phosphate Groups)/metabolism , Alteromonadaceae/genetics , Amino Acid Sequence , Bacterial Proteins/genetics , Biosynthetic Pathways/genetics , Cerulenin/pharmacology , Escherichia coli/drug effects , Escherichia coli/genetics , Fatty Acid Synthesis Inhibitors/pharmacology , Gene Expression Regulation, Bacterial , Metabolic Engineering/methods , Multigene Family , Polyketide Synthases/genetics , Reverse Transcriptase Polymerase Chain Reaction , Seawater/microbiology , Sequence Homology, Amino Acid , Transferases (Other Substituted Phosphate Groups)/genetics
20.
Appl Microbiol Biotechnol ; 100(16): 7239-48, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27270600

ABSTRACT

Acyl-CoAs are crucial compounds involved in essential metabolic pathways such as the Krebs cycle and lipid, carbohydrate, and amino acid metabolisms, and they are also key signal molecules involved in the transcriptional regulation of lipid biosynthesis in many organisms. In this study, we took advantage of the high selectivity of mass spectrometry and developed an ion-pairing reverse-phase high-pressure liquid chromatography electrospray ionization high-resolution mass spectrometry (IP-RP-HPLC/ESI-HRMS) method to carry on a comprehensive analytical determination of the wide range of fatty acyl-CoAs present in actinomycetes. The advantage of using a QTOF spectrometer resides in the excellent mass accuracy over a wide dynamic range and measurements of the true isotope pattern that can be used for molecular formula elucidation of unknown analytes. As a proof of concept, we used this assay to determine the composition of the fatty acyl-CoA pools in Mycobacterium, Streptomyces, and Corynebacterium species, revealing an extraordinary difference in fatty acyl-CoA amounts and species distribution between the three genera and between the two species of mycobacteria analyzed, including the presence of different chain-length carboxy-acyl-CoAs, key substrates of mycolic acid biosynthesis. The method was also used to analyze the impact of two fatty acid synthase inhibitors on the acyl-CoA profile of Mycobacterium smegmatis, which showed some unexpected low levels of C24 acyl-CoAs in the isoniazid-treated cells. This robust, sensitive, and reliable method should be broadly applicable in the studies of the wide range of bacteria metabolisms in which acyl-CoA molecules participate.


Subject(s)
Actinobacteria/metabolism , Acyl Coenzyme A/metabolism , Corynebacterium/metabolism , Fatty Acid Synthases/antagonists & inhibitors , Mycobacterium smegmatis/metabolism , Streptomyces/metabolism , Acyl Coenzyme A/analysis , Chromatography, High Pressure Liquid/methods , Fatty Acid Synthesis Inhibitors/pharmacology , Isoniazid/pharmacology , Lipid Metabolism/physiology , Spectrometry, Mass, Electrospray Ionization
SELECTION OF CITATIONS
SEARCH DETAIL
...